We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial

News   Apr 27, 2010

 
SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial
 
 
 

RELATED ARTICLES

Stem Cell Study Suggests Parkinson's Could Begin Before Birth

News

People who develop Parkinson's disease before age 50 may have been born with disordered brain cells that went undetected for decades, according to new Cedars-Sinai research. The research points to a drug that potentially might help correct these disease processes.

READ MORE

Gene Therapy for Duchenne Muscular Dystrophy Successful in Pigs

News

An interdisciplinary Munich research team led by scientists from TUM has for the first time succeeded in correcting the mutated dystrophin gene in living pigs. In order to cut the defective gene sequence from the DNA of the animals' muscle and heart cells, the researchers modified the Crispr-Cas9 gene scissors.

READ MORE

No Snake, No Problem – Scientists Produce Venom in a Dish

News

A new study published in the journal Cell outlines researchers' development of reptile organoids; specifically, organoids of the venom glands of the Cape coral snake. What's more, these organoids are capable of producing venom in vitro.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE